|Bid||17.88 x 0|
|Ask||17.89 x 0|
|Day's Range||17.03 - 17.88|
|52 Week Range||8.21 - 25.56|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.94%|
Cronos Group (CRON) reported its first-quarter earnings on May 15 with sales growth of almost 4.8x. Following the earnings release, the stock fell 5% on May 15 and fell another 3.4% on May 16 to 7.7 Canadian dollars. The company cut its recommendation to “sell” from “hold” but raised the price target to 6.5 Canadian dollars from 6 Canadian dollars.
With the anticipation of huge demand for cannabis, which translates into potential earnings growth, analysts are quite bullish on cannabis stocks in May. Most companies have seen increased bullishness over the last month, as we’ll discuss in this series. On May 15, Canopy Growth (WEED) stock was in the news again for its latest agreement to acquire Canopy Health Innovation and its subsidiary, Canopy Animal Health.
Cronos Group (CRON) reported its first-quarter earnings on May 15. The company’s sales rose almost 4.8 times year-over-year to 2.9 million Canadian dollars from 0.5 million Canadian dollars in the first quarter of 2017. Sequentially, sales grew 83% from 1.3 million Canadian dollars.
Today, Aurora Cannabis (ACB)(ACBFF) announced that it agreed to acquire all of MedReleaf’s (MEDFF) outstanding common shares for about 3.2 billion Canadian dollars. On the other hand, Aurora Cannabis stock fell almost 2.5% to 7.9 Canadian dollars. According to Aurora Cannabis’s press release, the acquisition price of 29.4 Canadian dollars implies a premium of 34% over both companies’ 20-day VWAP (volume-weighted average price) common shares as of May 11.
In the previous part of this series, we discussed how Canadian cannabis stocks’ (HMMJ) forward EV-to-EBITDA (enterprise value-to-earnings before interest, tax, depreciation, and amortization) multiple moved last week. In this part, we’ll compare how these producers’ multiples compare with each other.
Strong sentiment in the cannabis sector pushed ETFs and stocks into positive territory last week. The Horizons Marijuana Life Sciences ETF (HMMJ) closed 4.4% higher, while its US-listed counterpart, the Horizons Marijuana Life Sciences Index ETF (HMLSF), rose 4.8%. Similarly, the Emerging Marijuana Growers Index ETF (HMJR) rose 4.3%, and the Evolve Marijuana ETD (SEED) rose 2.5% between its close on May 4 and its close on May 11.
On May 8, Moody’s provided insights into the potential of the US and Canadian marijuana industries, discussing the potential impact of regulated medical and recreational marijuana on companies and governments. Here’s what Moody’s had to say. Moody’s vice president and senior analyst Grayson Nichols stated that tax revenue from the marijuana industry for state and local governments was only “marginally credit positive,” adding that for states such as Colorado and California, their share of annual fund revenue would remain small.
Last week was broadly positive for the cannabis sector. The ETF Horizons Marijuana Life Sciences (HMMJ) rose 2.4%, while the ETFMG Alternative Harvest ETF (MJ) rose 3.1% last week. On the other hand, the Horizons Emerging Marijuana Growers Index ETF (HMJR) fell 1.3%, while Evolve Marijuana ETF (SEED) fell by 79 basis points last week.
Is cannabis industry consolidating? On May 3, Aurora Cannabis (ACB) (ACBFF) and MedReleaf (MEDFF) were halted by the IIROC (Investment Industry Regulatory Organization of Canada) due to unusual trading levels on speculation of merger talks. Aurora Cannabis ended higher by 88 basis points at 8.02 Canadian dollars on May 3, while MedReleaf climbed as much as 2.2% to close at 22.25 Canadian dollars on the same day.
The Scotts Miracle-Gro Company (SMG) reported its 2Q18 earnings before the market opened today. It posted adjusted EPS (earnings per share) of $2.88, which missed analysts’ mean estimate of $3.31. The company’s core segment, U.S. Consumer, experienced a 6% year-over-year sales decline.
Last week (ended April 27), cannabis-sector ETFs ended in negative territory. The Horizons Marijuana Life Sciences ETF (HMMJ) fell ~4.1%, the Horizons Emerging Marijuana Growers Index ETF (HMJR) fell ~3.8%, and the ETFMG Alternative Harvest ETF (MJ) fell ~4.4%.
Yesterday, April 30, Canopy Growth (WEED) rose 10% and closed the day at $30.10 Canadian. The broader cannabis market was also higher with the Horizons Marijuana Life Science ETF (HMMJ) ending the day 3% higher and Aurora Cannabis (ACB), MedReleaf (MEDFF), and Hydropothecary (HYYDF) each gaining 6%. What moved cannabis stocks?
In the previous part of this series, we compared the forward EV-to-sales multiples of individual cannabis licensed producers (HMMJ) with the peers’ median on April 26. We’ll do a similar comparison for the EV-to-EBITDA1 multiple as well.
Scotts Miracle-Gro (SMG) will announce its fiscal 2Q18 earnings before markets open on May 1. The mean EPS (earnings per share) estimate is $3.38, which is a 21% increase compared to EPS of $2.8 in 2Q17. Investors will pay close attention to Scotts Miracle-Gro Company’s progress in its indoor gardening segment, Hawthorne. The Hawthorne segment is primarily focused on the emerging cannabis sector (HMMJ), which has given SMG stock a boost in the last two years.
On April 20, the cannabis sector saw more positive news came from the US, as Senator Chuck Schumer discussed intentions to introduce legislation decriminalizing cannabis, which currently is a Schedule 1 drug in the US.
Last week (ended April 13), overall market sentiment was positive, with the S&P 500 rising 2% and the TSX 30 gaining 44 basis points. The cannabis sector ended the week positively, breaking its losing streak.
The legalized-marijuana movement will likely welcome the news Wednesday that two prominent former politicians are joining a cannabis company.
On April 11, Hydropothecary (HYYDF) stock surged 13.2% after it became the SAQ’s (Société des alcools du Québec) preferred non-medical cannabis supplier once non-medical cannabis becomes legal in Canada. The company’s press release stated that the agreement term extends to the first five years following legalization and has an option to extend for another year.
Horizons Marijuana Life Sciences Index ETF Celebrates Its One-Year Anniversary with the Best 12-Month ETF Performance in Canada
Last week, the S&P 500 Index (SPY) ended up with a fall of 1.4%, and the TSX 300 Composite Index ended the week with a fall of nearly 1%.
As of April 4, markets continued to weigh down on the cannabis sector for the third straight day in a row. The Horizons Marijuana Life Science ETF (HMMJ) ended almost 80 basis points lower than its previous day’s close. This ETF is down almost 27%, indicating weakness in the cannabis sector YTD (year-to-date).
Hydropothecary (HYYDF) reported a fall during fiscal 2Q18 due to a big increase in its operating expense YoY (year-over-year). The company’s operating expense rose from 1.7 million Canadian dollars in fiscal 2Q17 to 5.5 million Canadian dollars in fiscal 2Q18. Standardizing this as a percentage of its sales, Hydropothecary’s operating expenses rose from 1.9x its sales in fiscal 2Q17 to 4.6x its sales in fiscal 2Q18.